Chitin and Chitosan in 3D Printing: Practical Bioink, Scaffold and Smart Material Design for Tissue Engineering

The versatility of chitin and chitosan in 3D bioprinting, powering the future of scaffolds, tissue models, and smart biomaterials.

Chitin and chitosan are now credible workhorse polymers for 3D printing and bioprinting, particularly when formulated as hydrogels and composites for tissue engineering, drug delivery and emerging smart materials (Lazaridou et al, 2022). This article surveys the main application families with a practical lens, and outlines how a partner such as Entoplast can help teams move from concept to robust products (Taghizadeh et al, 2022).

Why chitin and chitosan for 3D (bio)printing?

Chitin is a structural polysaccharide found in crustacean shells and insect cuticle; chitosan is its partially deacetylated, cationic derivative, typically soluble in mild acids and readily processed into hydrogels, films and fibres (Ahmadi et al, 2015). Their appeal in 3D printing and bioprinting comes from a combination of biocompatibility, biodegradability, intrinsic antibacterial activity and mucoadhesive, charge‑based interactions with cells and proteins (Samal et al, 2023).

Additive manufacturing has made it routine to fabricate patient‑specific and highly porous constructs; the bottleneck is finding ink and scaffold materials that can be printed at scale while still providing appropriate mechanical support and biological signalling (Demirtaş et al, 2020). Chitosan and chitin derivatives sit in an interesting middle ground: mechanically modest in their native form, but highly tunable via blends, crosslinking and fillers, with a growing body of data on cell response and tissue integration (Lazaridou et al, 2022).

Entoplast’s focus is on supplying well‑characterised chitin and chitosan – including black soldier fly (BSF)‑derived streams – with controlled molecular weight and degree of deacetylation (DD), tailored for these biofabrication workflows (Dewi et al, 2025).

Chitosan hydrogel bioinks and soft scaffolds

Most chitosan bioinks are water‑rich hydrogels formulated for extrusion‑based bioprinting of soft tissue constructs, including skin, cartilage, nerve and generic soft tissue models (Lazaridou et al, 2022).

Rheology and printability

An effective chitosan bioink needs shear‑thinning behaviour (viscosity decreasing under shear) to flow through a nozzle without excessive pressure, then rapidly recover structure to hold complex geometries (Taghizadeh et al, 2022). Taghizadeh et al. report that chitosan solutions can be tuned into the 30 mPa·s–10⁷ mPa·s window required for micro‑extrusion bioprinting by adjusting concentration, acid content and additives, with yield stresses in the hundreds of pascals and gelation times below 10 seconds in many systems (Taghizadeh et al, 2022).

Thermogelling chitosan–glycerophosphate bioinks, as used by Li and co‑workers for cartilage constructs and by Maturavongsadit and colleagues for bone‑oriented scaffolds, show gelation in under 7 seconds at 37 °C, with complex viscosities in the 10–40 Pa·s range and good recovery of storage modulus after simulated extrusion (Maturavongsadit et al, 2021). These rheological profiles support layer fidelity and high cell viability when printing at moderate pressures around 12–20 kPa (Maturavongsadit et al, 2021).

Mechanical properties and cell environment

Native chitosan hydrogels are relatively weak and prone to swelling, so most systems rely on composite design to mimic aspects of extracellular matrix mechanics (Demirtaş et al, 2020). Strategies include combining chitosan with gelatin or collagen to introduce cell‑adhesion motifs and improve elasticity, incorporating nanocellulose to raise modulus and osteogenic differentiation, and using crosslinkers such as genipin or methacrylate groups to increase tensile or compressive strength while maintaining cell viability (Lazaridou et al, 2022).

Porosity and pore interconnectivity are controlled via printing path (infill, layer spacing) and post‑processing, enabling diffusion of nutrients and the creation of ECM‑like microenvironments for encapsulated or seeded cells (Demirtaş et al, 2020).

Key challenges

An illustrative summary of the primary technical hurdles in formulating and printing pure chitosan hydrogels for tissue engineering.

Reviews consistently highlight slow gelation and weak mechanics in pure chitosan hydrogels, necessitating blends and supramolecular or covalent crosslinking to reach practical performance (Taghizadeh et al, 2022). There is also a delicate balance between viscosity, print resolution, shear stress on cells and long‑term stability; high polymer content improves fidelity but can reduce cell viability if pressures or nozzle diameters are not optimised (Lazaridou et al, 2022).

Composite and load‑bearing scaffolds

For bone and cartilage, chitosan is usually part of a composite aimed at combining osteoconductivity, controlled degradation and load‑bearing capability (Demirtaş et al, 2020).

Nanocellulose–chitosan and polymer composites

Nanocellulose/chitosan bioinks reported by Maturavongsadit and colleagues are designed to increase viscosity and mechanical stiffness while promoting osteogenesis (Maturavongsadit et al, 2021). In these systems, cellulose nanocrystals at 0.5–1.5% w/v significantly raise storage modulus and support upregulation of alkaline phosphatase, calcium mineralisation and extracellular matrix formation in MC3T3‑E1 pre‑osteoblasts (Maturavongsadit et al, 2021).

Other studies summarised by Lazaridou and co‑workers describe chitosan combined with poly(ε‑caprolactone) frames for articular cartilage repair, where chitosan fills a 3D‑printed PCL lattice and provides a cell‑friendly hydrogel phase inside a mechanically robust framework (Lazaridou et al, 2022). Chitosan–gelatin–hydroxyapatite blends and tricalcium phosphate/chitosan–collagen constructs likewise show compressive strengths approaching trabecular bone while maintaining bioactivity for bone regeneration (Demirtaş et al, 2020).

Pectin, collagen and mineral fillers

Taghizadeh and co‑authors discuss chitosan–pectin and chitosan–collagen hydrogels printed into structured scaffolds with tailored pore architectures for osteochondral repair, using ionic crosslinking and freeze–thaw processing to tune stiffness and swelling behaviour (Taghizadeh et al, 2022). Ceramic fillers such as nano‑hydroxyapatite, bioactive glass and calcium phosphate further enhance osteoconductivity and protein adsorption, but also change viscosity and gelation behaviour, requiring re‑optimisation of printing pressures and nozzle sizes (Demirtaş et al, 2020).

A practical question for R&D teams is how to match degradation rate to tissue regeneration timelines: higher DD chitosan, denser crosslinking and ceramic content generally slow degradation, whereas more amorphous, lower DD matrices degrade faster under lysozyme and related enzymes (Samal et al, 2023).

3D‑printed chitosan constructs for drug delivery

Chitosan’s cationic, mucoadhesive nature and ability to form polyelectrolyte complexes make it attractive for 3D‑printed drug‑delivery systems, including local depots and personalised dosage forms (Ahmadi et al, 2015).

Lazaridou and co‑workers review multiple constructs where chitosan scaffolds are loaded with antibiotics, growth factors or analgesics, using printing geometry – such as infill ratio, channel networks and shell–core designs – to modulate release profiles (Lazaridou et al, 2022). Examples include chitosan–pectin dressings loaded with lidocaine that show a rapid initial release followed by sustained delivery, and chitosan–calcium phosphate scaffolds carrying BMP‑2 or VEGF that provide weeks of controlled release linked to scaffold erosion (Lazaridou et al, 2022).

Design variables include geometry and internal architecture, crosslinking density and blending choices, all of which influence whether release is dominated by diffusion, erosion or bulk degradation (Ahmadi et al, 2015). Regulatory and operationally, teams must consider whether these constructs are regulated as medical devices, medicinal products or combination products, which drives requirements for pharmacokinetics, sterility assurance and batch‑to‑batch reproducibility (Samal et al, 2023).

Chitosan in 3D/4D smart materials

4D printing refers to constructs that change shape or function over time or in response to stimuli, often using smart hydrogels with responsive chemistries (Samal et al, 2023). In their review of chitosan in 3D/4D printing, Samal and colleagues outline pH‑responsive, temperature‑responsive and photo‑responsive chitosan derivatives and composites used to create shape‑morphing, self‑healing or stimuli‑triggered drug‑delivery platforms (Samal et al, 2023).

Examples include glycol chitosan/oxidised hyaluronate ferrogels that bend or recover shape under magnetic fields, phenol‑modified chitosan hydrogels crosslinked with PEG derivatives that show self‑healing and adhesiveness, and thermo‑responsive chitosan–poly(N‑isopropylacrylamide) systems where lower critical solution temperature tuning allows constructs to swell or shrink with temperature (Samal et al, 2023).

From a commercial standpoint, most chitosan‑based 4D systems are still at proof‑of‑concept stage; mechanical robustness, long‑term cycling stability and regulatory pathways for shape‑changing implants remain open questions, so near‑term opportunities are more likely in responsive wound dressings, organ‑on‑chip platforms and research models than in fully implantable devices (Taghizadeh et al, 2022).

Biological performance: what do evaluation studies show?

Across reviews and primary studies, chitosan‑based 3D‑printed constructs generally show good cell viability, adhesion and differentiation, but performance is highly formulation‑dependent (Lazaridou et al, 2022).

Lazaridou et al. summarise multiple in vitro and in vivo studies where osteoblasts, mesenchymal stem cells, chondrocytes and fibroblasts maintain above 80–90% viability post‑printing in well‑optimised composite inks, and where chitosan–hydroxyapatite and chitosan–calcium phosphate scaffolds support bone ingrowth and integration in small‑animal models without adverse immune responses (Lazaridou et al, 2022).

Maturavongsadit et al. show that nanocellulose/chitosan bioinks significantly enhance osteogenic markers such as alkaline phosphatase, calcium deposition and extracellular matrix formation compared to chitosan alone (Maturavongsadit et al, 2021).

For insect‑derived chitosan, Dewi and co‑workers report that BSF pupae chitosan gel applied to extraction sockets in guinea pigs increases osteoblast numbers and reduces osteoclast numbers over 21 days compared to controls, supporting bone regeneration in vivo (Dewi et al, 2025). Antibacterial behaviour is also well documented, with chitosan’s positive charge disrupting bacterial membranes and reducing biofilm formation on printed scaffolds, an effect particularly valuable in dental and orthopaedic contexts (Demirtaş et al, 2020).

Practical design and scale‑up considerations

A multi-stage overview of translating chitin- and chitosan-based bioinks from laboratory research to reproducible, industrial-scale production.

Polymer selection and specification

Choosing between chitin, chitosan and derivatives hinges on solubility, printability and target bioactivity, and most 3D bioprinting applications favour medium‑molecular‑weight chitosan with DD in the 70–90% range to balance viscosity, degradation and charge density (Taghizadeh et al, 2022). Chitosan oligosaccharides or carboxymethyl chitosan are used where higher solubility at neutral pH or faster degradation is needed, while grafted or methacrylated chitosan enables photo‑curing and dual crosslinking for higher shape fidelity (Samal et al, 2023).

Specification windows for base polymer – including molecular‑weight distribution, DD, ash and protein content, and residual solvent limits – should be set early, as rheology and biological behaviour are sensitive to batch variation and can undermine reproducibility if not controlled (Demirtaş et al, 2020). Working with a specialised supplier such as Entoplast, who can deliver defined MW/DD ranges and traceable BSF or crustacean streams, reduces formulation risk and supports regulatory dossiers for advanced medical and bioink applications (Dewi et al, 2025).

Process integration and manufacturing

On the process side, teams need robust protocols for sterile handling and mixing of chitosan solutions, including degassing to avoid bubbles that disrupt print paths and controlling nozzle wear and clogging, particularly in ceramic‑filled inks (Lazaridou et al, 2022). Printing parameters such as nozzle diameter, pressure and speed must be optimised to limit shear damage to encapsulated cells while maintaining resolution, and printing temperature should be kept close to physiological conditions when cells are involved (Demirtaş et al, 2020).

Scale‑up from benchtop printers to GMP‑compliant lines involves batch‑to‑batch consistency in polymer and ink properties, documentation of processing steps, and validated quality control using tools such as FTIR, SEC, rheology and mechanical testing, alongside validated sterilisation methods like gamma irradiation or ethylene oxide that do not unduly compromise chitosan’s mechanical or antibacterial properties (Ahmadi et al, 2015).

Regulatory and risk landscape

Regulators generally view chitosan as biocompatible and biodegradable, with precedent in drug‑delivery and wound‑care devices, but each new 3D‑printed construct must be assessed on its own merits and within its specific regulatory framework (Ahmadi et al, 2015).

Key points include clear classification as a medical device, advanced therapy medicinal product or combination product, depending on whether the construct delivers active substances or cells; full material characterisation including source, impurities, endotoxin levels and residual crosslinkers; and robust preclinical data on safety, reproducibility and performance, including mechanical fatigue and wear for load‑bearing implants and contamination control and batch consistency for bioinks (Lazaridou et al, 2022).

Building regulatory strategy in parallel with technical development – rather than as an afterthought – helps avoid redesigns and supports smoother clinical translation, particularly for novel composites and BSF‑derived chitosan streams where regulatory familiarity is still developing (Dewi et al, 2025).

Where chitin/chitosan are most promising now

Drawing these strands together, the strongest near‑term opportunities are in hydrogel bioinks for soft tissue models and research‑grade bioprinting platforms, composite scaffolds for bone and cartilage, and advanced wound dressings and local drug‑delivery depots that leverage chitosan’s mucoadhesive and antibacterial behaviour.

More speculative, but high‑potential, areas include 4D smart constructs, complex multi‑compartment drug‑delivery architectures and fully patient‑specific load‑bearing implants where chitosan is the primary structural material, where mechanical limitations, sensitivity to polymer batch properties and limited clinical‑level evidence call for careful risk–benefit analysis and staged development.

Entoplast’s role is to provide the consistent chitin and chitosan feedstocks and technical support needed to explore these applications without compromising regulatory‑grade quality or sustainability, particularly via BSF‑derived streams aligned with circular‑economy goals.